Analyzing heterogeneity in Alzheimer Disease using multimodal normative modeling on imaging-based ATN biomarkers
Authors:
Sayantan Kumar,
Tom Earnest,
Braden Yang,
Deydeep Kothapalli,
Andrew J. Aschenbrenner,
Jason Hassenstab,
Chengie Xiong,
Beau Ances,
John Morris,
Tammie L. S. Benzinger,
Brian A. Gordon,
Philip Payne,
Aristeidis Sotiras
Abstract:
INTRODUCTION: Previous studies have applied normative modeling on a single neuroimaging modality to investigate Alzheimer Disease (AD) heterogeneity. We employed a deep learning-based multimodal normative framework to analyze individual-level variation across ATN (amyloid-tau-neurodegeneration) imaging biomarkers.
METHODS: We selected cross-sectional discovery (n = 665) and replication cohorts (…
▽ More
INTRODUCTION: Previous studies have applied normative modeling on a single neuroimaging modality to investigate Alzheimer Disease (AD) heterogeneity. We employed a deep learning-based multimodal normative framework to analyze individual-level variation across ATN (amyloid-tau-neurodegeneration) imaging biomarkers.
METHODS: We selected cross-sectional discovery (n = 665) and replication cohorts (n = 430) with available T1-weighted MRI, amyloid and tau PET. Normative modeling estimated individual-level abnormal deviations in amyloid-positive individuals compared to amyloid-negative controls. Regional abnormality patterns were mapped at different clinical group levels to assess intra-group heterogeneity. An individual-level disease severity index (DSI) was calculated using both the spatial extent and magnitude of abnormal deviations across ATN.
RESULTS: Greater intra-group heterogeneity in ATN abnormality patterns was observed in more severe clinical stages of AD. Higher DSI was associated with worse cognitive function and increased risk of disease progression.
DISCUSSION: Subject-specific abnormality maps across ATN reveal the heterogeneous impact of AD on the brain.
△ Less
Submitted 1 July, 2024; v1 submitted 4 April, 2024;
originally announced April 2024.
Gene-SGAN: a method for discovering disease subtypes with imaging and genetic signatures via multi-view weakly-supervised deep clustering
Authors:
Zhijian Yang,
Junhao Wen,
Ahmed Abdulkadir,
Yuhan Cui,
Guray Erus,
Elizabeth Mamourian,
Randa Melhem,
Dhivya Srinivasan,
Sindhuja T. Govindarajan,
Jiong Chen,
Mohamad Habes,
Colin L. Masters,
Paul Maruff,
Jurgen Fripp,
Luigi Ferrucci,
Marilyn S. Albert,
Sterling C. Johnson,
John C. Morris,
Pamela LaMontagne,
Daniel S. Marcus,
Tammie L. S. Benzinger,
David A. Wolk,
Li Shen,
Jingxuan Bao,
Susan M. Resnick
, et al. (3 additional authors not shown)
Abstract:
Disease heterogeneity has been a critical challenge for precision diagnosis and treatment, especially in neurologic and neuropsychiatric diseases. Many diseases can display multiple distinct brain phenotypes across individuals, potentially reflecting disease subtypes that can be captured using MRI and machine learning methods. However, biological interpretability and treatment relevance are limite…
▽ More
Disease heterogeneity has been a critical challenge for precision diagnosis and treatment, especially in neurologic and neuropsychiatric diseases. Many diseases can display multiple distinct brain phenotypes across individuals, potentially reflecting disease subtypes that can be captured using MRI and machine learning methods. However, biological interpretability and treatment relevance are limited if the derived subtypes are not associated with genetic drivers or susceptibility factors. Herein, we describe Gene-SGAN - a multi-view, weakly-supervised deep clustering method - which dissects disease heterogeneity by jointly considering phenotypic and genetic data, thereby conferring genetic correlations to the disease subtypes and associated endophenotypic signatures. We first validate the generalizability, interpretability, and robustness of Gene-SGAN in semi-synthetic experiments. We then demonstrate its application to real multi-site datasets from 28,858 individuals, deriving subtypes of Alzheimer's disease and brain endophenotypes associated with hypertension, from MRI and SNP data. Derived brain phenotypes displayed significant differences in neuroanatomical patterns, genetic determinants, biological and clinical biomarkers, indicating potentially distinct underlying neuropathologic processes, genetic drivers, and susceptibility factors. Overall, Gene-SGAN is broadly applicable to disease subtyping and endophenotype discovery, and is herein tested on disease-related, genetically-driven neuroimaging phenotypes.
△ Less
Submitted 25 January, 2023;
originally announced January 2023.
